ESGCT 2017 in Berlin: Clear Steps Forward.
作者信息
Ylä-Herttuala Seppo
机构信息
A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio 70211, Finland.
出版信息
Mol Ther. 2017 Dec 6;25(12):2599. doi: 10.1016/j.ymthe.2017.11.003. Epub 2017 Nov 28.
Abstract
摘要
相似文献
1
ESGCT 2017 in Berlin: Clear Steps Forward.
Mol Ther. 2017 Dec 6;25(12):2599. doi: 10.1016/j.ymthe.2017.11.003. Epub 2017 Nov 28.
2
Spring Forward: ESGCT Trains the Next Generation of Gene and Cell Therapists.
Hum Gene Ther. 2018 Oct;29(10):1074-1075. doi: 10.1089/hum.2018.29076.vmw.
3
The pitfalls in the development of biologic therapy.
Nat Clin Pract Rheumatol. 2007 Jan;3(1):1. doi: 10.1038/ncprheum0373.
4
bioLOGIC Europe 2007--Terrapinn's eighth annual conference.
IDrugs. 2007 Aug;10(8):543-8.
5
Economics of biological therapies.
BMJ. 2009 Aug 21;339:b3276. doi: 10.1136/bmj.b3276.
6
Innovation and competition in advanced therapy medicinal products.
EMBO Mol Med. 2019 Mar;11(3). doi: 10.15252/emmm.201809992.
7
European Society of Gene and Cell Therapy (ESGCT) at 25: A Gene Therapy Community at Its Prime and on the Move.
Hum Gene Ther. 2017 Nov;28(11):940. doi: 10.1089/hum.2017.29049.trf.
8
The non-small-cell lung cancer drug market.
Nat Rev Drug Discov. 2016 Apr;15(4):229-30. doi: 10.1038/nrd.2016.42.
9
Promising compounds portend major management problems.
Manag Care. 2003 Apr;12(4):48-9.
10
The Science Behind Biosimilars: Entering a New Era of Biologic Therapy.
Arthritis Rheumatol. 2018 Mar;70(3):334-344. doi: 10.1002/art.40388. Epub 2018 Feb 7.
Zotero 插件